GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Belite Bio Inc (NAS:BLTE) » Definitions » Return-on-Tangible-Asset

Belite Bio (Belite Bio) Return-on-Tangible-Asset : -32.70% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Belite Bio Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Belite Bio's annualized Net Income for the quarter that ended in Mar. 2024 was $-31.48 Mil. Belite Bio's average total tangible assets for the quarter that ended in Mar. 2024 was $96.28 Mil. Therefore, Belite Bio's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was -32.70%.

The historical rank and industry rank for Belite Bio's Return-on-Tangible-Asset or its related term are showing as below:

BLTE' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -46.64   Med: -42.14   Max: -22.35
Current: -46.49

During the past 4 years, Belite Bio's highest Return-on-Tangible-Asset was -22.35%. The lowest was -46.64%. And the median was -42.14%.

BLTE's Return-on-Tangible-Asset is ranked worse than
54.98% of 1546 companies
in the Biotechnology industry
Industry Median: -40.335 vs BLTE: -46.49

Belite Bio Return-on-Tangible-Asset Historical Data

The historical data trend for Belite Bio's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Belite Bio Return-on-Tangible-Asset Chart

Belite Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
-22.35 -43.85 -40.42 -46.64

Belite Bio Quarterly Data
Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -65.62 -54.22 -73.95 -37.53 -32.70

Competitive Comparison of Belite Bio's Return-on-Tangible-Asset

For the Biotechnology subindustry, Belite Bio's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Belite Bio's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Belite Bio's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Belite Bio's Return-on-Tangible-Asset falls into.



Belite Bio Return-on-Tangible-Asset Calculation

Belite Bio's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-31.632/( (44.242+91.407)/ 2 )
=-31.632/67.8245
=-46.64 %

Belite Bio's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-31.484/( (91.407+101.147)/ 2 )
=-31.484/96.277
=-32.70 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


Belite Bio  (NAS:BLTE) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Belite Bio Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Belite Bio's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Belite Bio (Belite Bio) Business Description

Traded in Other Exchanges
Address
12750 High Bluff Drive, Suite 475, San Diego, CA, USA, 92130
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.